Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06551649
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Contrasting Chronic Inflammation and Neurodegeneration Using the Human Amniotic Mesenchymal Cell Secretome as an Innovative Therapeutic Strategy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONTRASTOME
Brief Summary:
Neurodegenerative diseases are debilitating conditions characterized by chronic inflammation leading to dysfunction of both the non-neuronal cellular components of the central nervous system and peripheral blood immune cells Thus it is crucial to develop an innovative therapeutic strategy that not only effectively contrast neurodegeneration but also aims to reduce inflammation
The overall aim of the study is to provide a preclinical in vitro demonstration of the immunomodulatory and pro-regenerative potential of the human amniotic mesenchymal stromal cell hAMSC secretome in counteracting neurodegeneration
This potential will be evaluated in three-dimensional in vitro models of neurodegenerative diseases such as amyotrophic lateral sclerosis ALS and chronic demyelinating disease multiple sclerosis - MS To this end the study includes sample collection from patients without pharmacological treatment and without medical devices Patients diagnosed with ALS patients diagnosed with MS and healthy volunteers will be recruited to collect blood samples and skin biopsies Patient-specific and control organoid platforms mimicking cellular heterogeneity and tridimensional interactions within the central nervous system including the inflammatory compartment will be developed to be used as a valuable tool to investigate the in vitro efficacy of the hAMSC secretome
The overall aim of the study is to provide a preclinical in vitro demonstration of the immunomodulatory and pro-regenerative potential of the human amniotic mesenchymal stromal cell hAMSC secretome in counteracting neurodegeneration
This potential will be evaluated in three-dimensional in vitro models of neurodegenerative diseases such as amyotrophic lateral sclerosis ALS and chronic demyelinating disease multiple sclerosis - MS To this end the study includes sample collection from patients without pharmacological treatment and without medical devices Patients diagnosed with ALS patients diagnosed with MS and healthy volunteers will be recruited to collect blood samples and skin biopsies Patient-specific and control organoid platforms mimicking cellular heterogeneity and tridimensional interactions within the central nervous system including the inflammatory compartment will be developed to be used as a valuable tool to investigate the in vitro efficacy of the hAMSC secretome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None